XTX Topco Ltd Acquires Shares of 13,748 Exelixis, Inc. (NASDAQ:EXEL)

XTX Topco Ltd bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the second quarter, Holdings Channel reports. The institutional investor bought 13,748 shares of the biotechnology company’s stock, valued at approximately $309,000.

A number of other institutional investors and hedge funds have also modified their holdings of EXEL. LSV Asset Management increased its stake in shares of Exelixis by 107.7% during the second quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock worth $129,511,000 after purchasing an additional 2,989,021 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in Exelixis by 948.3% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock valued at $58,240,000 after purchasing an additional 2,220,150 shares during the last quarter. Jupiter Asset Management Ltd. boosted its holdings in Exelixis by 148.2% in the 1st quarter. Jupiter Asset Management Ltd. now owns 2,267,894 shares of the biotechnology company’s stock valued at $53,817,000 after purchasing an additional 1,354,062 shares during the last quarter. Swedbank AB acquired a new position in Exelixis in the 1st quarter valued at about $22,455,000. Finally, First Trust Advisors LP lifted its holdings in shares of Exelixis by 18.5% in the 4th quarter. First Trust Advisors LP now owns 3,152,755 shares of the biotechnology company’s stock worth $75,635,000 after acquiring an additional 492,613 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. JMP Securities restated a “market outperform” rating and issued a $29.00 price objective on shares of Exelixis in a report on Friday, September 20th. HC Wainwright reissued a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Wednesday, September 18th. UBS Group assumed coverage on shares of Exelixis in a research report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price objective on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $27.00 target price on shares of Exelixis in a research report on Thursday. Finally, Truist Financial reiterated a “buy” rating and set a $33.00 price target (up previously from $32.00) on shares of Exelixis in a research note on Thursday, August 8th. Five research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $27.67.

Exelixis Stock Down 1.1 %

Shares of NASDAQ EXEL opened at $25.96 on Friday. Exelixis, Inc. has a 52 week low of $18.64 and a 52 week high of $27.83. The firm has a 50-day moving average price of $25.56 and a 200 day moving average price of $23.48. The stock has a market capitalization of $7.41 billion, a price-to-earnings ratio of 40.56, a price-to-earnings-growth ratio of 0.56 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The firm had revenue of $637.18 million during the quarter, compared to the consensus estimate of $468.21 million. Equities research analysts expect that Exelixis, Inc. will post 1.59 EPS for the current fiscal year.

Insider Buying and Selling at Exelixis

In other news, CFO Christopher J. Senner sold 125,000 shares of Exelixis stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the sale, the chief financial officer now directly owns 721,680 shares in the company, valued at $19,622,479.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director George Poste sold 33,725 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $26.89, for a total value of $906,865.25. Following the sale, the director now directly owns 199,020 shares of the company’s stock, valued at $5,351,647.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christopher J. Senner sold 125,000 shares of Exelixis stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the transaction, the chief financial officer now directly owns 721,680 shares in the company, valued at $19,622,479.20. The disclosure for this sale can be found here. In the last three months, insiders sold 327,858 shares of company stock worth $8,640,129. 2.85% of the stock is owned by corporate insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.